Synthetic Progestin

Synthetic Progestin Market Outlook

The global synthetic progestin market is projected to reach approximately USD 4.2 billion by 2035, growing at a compound annual growth rate (CAGR) of 6.2% from 2025 to 2035. This growth can be attributed to several factors including the increasing prevalence of contraceptive use, rising awareness of hormone-related disorders, and advancements in the development of synthetic progestins that offer safer and more effective options for patients. Additionally, the growing trend of self-medication and the increasing availability of online pharmacies are further expected to drive market growth. The heightened focus on women's health and reproductive rights is also contributing to the expansion of this market segment significantly.

Growth Factor of the Market

The growth of the synthetic progestin market can be mainly attributed to the rising awareness about women's reproductive health and an increasing incidence of hormonal disorders. The increasing demand for effective contraceptive options also plays a significant role in market expansion, as more women seek reliable and safe methods to manage family planning. Furthermore, advancements in pharmaceutical research have led to the development of innovative synthetic progestin formulations that offer improved efficacy and reduced side effects, appealing to a larger patient demographic. The rising healthcare expenditure and the improved access to healthcare services are also crucial factors driving the market. Additionally, the growing trend towards hormone replacement therapy, particularly in aging populations, is creating more opportunities for the synthetic progestin market.

Key Highlights of the Market

• Projected global market size of USD 4.2 billion by 2035, growing at a CAGR of 6.2%.
• Increasing demand for safe and effective contraceptive options.
• Advancements in technology leading to innovative formulations.
• Rising awareness of women's reproductive health issues.
• Growing trend towards hormone replacement therapy in aging populations.

By Product Type

Oral Contraceptives:

Oral contraceptives hold a significant share in the synthetic progestin market owing to their ease of use and effectiveness in preventing pregnancy. These contraceptives typically contain a combination of estrogen and progestin, or progestin alone, and are utilized by millions of women globally. The accessibility of these products through pharmacies and clinics further enhances their adoption. Current trends show a growing preference for lower-dose formulations, which reduce the risk of side effects while still providing effective contraception. Continuous education about the benefits of oral contraceptives is encouraging more women to utilize them as a primary form of birth control.

Injectable Progestins:

Injectable progestins are gaining traction in the synthetic progestin market due to their long-lasting effects, typically requiring administration only once every three months. This ease of use is particularly appealing to women who prefer a no-fuss method of contraception without the daily commitment that oral contraceptives demand. The efficacy of injectable options in preventing pregnancy is a significant driver of their popularity, particularly in regions where access to healthcare services may be limited. Additionally, the convenience of receiving injections during routine medical visits enhances compliance, contributing to the growth of this segment.

Progestin-releasing Intrauterine Devices:

Progestin-releasing intrauterine devices (IUDs) represent a rapidly growing segment of the synthetic progestin market, providing a long-term contraceptive solution that can last for several years. These devices release progestin directly into the uterus, resulting in high contraceptive efficacy and minimal systemic side effects. The popularity of IUDs is supported by increasing awareness of their benefits, including reduced menstrual bleeding and lower risk of certain reproductive cancers. As healthcare providers continue to educate patients about this method, its adoption is expected to rise significantly, further elevating its market share.

Progestin Implants:

Progestin implants are another innovative contraceptive option that is contributing to the growth of the synthetic progestin market. These small rods are implanted under the skin of the upper arm and release hormones over a period of several years to prevent pregnancy. The major advantages of this method include high efficacy, long duration of action, and the convenience of not having to think about contraception daily. As more women seek out long-term, reversible contraceptive options that require minimal maintenance, progestin implants are likely to see increased usage. The ongoing research to improve the formulations and reduce side effects will also boost this segment’s growth.

Progestin Creams:

Progestin creams are emerging as an alternative option within the synthetic progestin market, particularly for those who prefer non-invasive methods of hormone administration. These creams can be applied topically and are utilized for various applications such as hormone replacement therapy and alleviating symptoms associated with menstrual disorders. The rising awareness of the benefits of transdermal delivery systems, which can minimize gastrointestinal side effects, is fostering the growth of this product type. As research continues to demonstrate the effectiveness of progestin creams, their acceptance among consumers is expected to increase.

By Application

Contraception:

Contraception is the leading application segment within the synthetic progestin market, driven by the increasing need for effective family planning options. Women across the globe are seeking reliable contraceptive methods to prevent unintended pregnancies, thereby propelling the demand for synthetic progestins. The variety of options available, including oral contraceptives, injectables, and IUDs, caters to diverse preferences and lifestyles, making them widely accessible. Furthermore, educational initiatives to promote reproductive health and contraception awareness are crucial in reinforcing this demand. As societal attitudes toward family planning continue to evolve, contraception is expected to remain a dominant application in the synthetic progestin market.

Menstrual Disorders:

The treatment of menstrual disorders represents a substantial and growing application segment for synthetic progestins. Various hormonal imbalances can lead to conditions such as polycystic ovary syndrome (PCOS), endometriosis, and heavy menstrual bleeding, which often require medical intervention. Synthetic progestins are commonly prescribed to help regulate menstrual cycles, alleviate symptoms, and manage these disorders. The rising prevalence of such conditions, along with increasing patient awareness about treatment options, is fostering demand for synthetic progestins in managing menstrual disorders. The continuous advancements in formulations are also enhancing their effectiveness and safety profiles, contributing to market growth.

Hormone Replacement Therapy:

Hormone replacement therapy (HRT) is another significant application segment of the synthetic progestin market, particularly among menopausal women seeking relief from symptoms associated with estrogen deficiency. Synthetic progestins are often used in conjunction with estrogen to reduce the risks associated with estrogen-only therapy, such as endometrial hyperplasia. The increasing aging population globally is driving the demand for HRT, as more women seek effective solutions to manage menopausal symptoms like hot flashes and mood swings. As awareness about the benefits of HRT continues to expand among healthcare providers and patients, the adoption of synthetic progestins in this application is anticipated to grow steadily.

Endometriosis:

Endometriosis is a painful condition that affects many women, leading to demand for effective therapies, including synthetic progestins. These hormones play a crucial role in managing the symptoms of endometriosis by suppressing ovulation and reducing the growth of endometrial tissue. The increasing diagnosis rates and awareness surrounding endometriosis are propelling the demand for therapeutic options that include synthetic progestins. As more research is conducted to understand the condition and develop tailored treatment plans, synthetic progestins are likely to gain a more prominent place in the management of endometriosis, thereby driving this application segment's growth.

Others:

In addition to the major applications mentioned, there are several other uses of synthetic progestins that contribute to the market's complexity. These may include treatments for conditions such as premenstrual syndrome (PMS), infertility, and certain cancers. The versatility of synthetic progestins makes them applicable in various therapeutic scenarios, reinforcing their importance in modern medicine. The growing exploration of their potential in these additional areas is expected to spur interest and increase demand, further enhancing the overall growth of the synthetic progestin market. As healthcare professionals gain a deeper understanding of the hormone's effects, new applications are likely to emerge, providing further opportunities for market expansion.

By Distribution Channel

Hospitals & Clinics:

The hospitals and clinics segment remains a primary distribution channel for synthetic progestins, driven by the essential role healthcare providers play in prescribing these medications. Patients often receive prescriptions following consultations, especially for conditions requiring medical intervention, such as menstrual disorders or hormone replacement therapy. The presence of trained healthcare professionals in hospitals and clinics ensures that patients receive appropriate guidance regarding the use and implications of synthetic progestins. As the focus on women's reproductive health continues to rise, hospitals and clinics are also investing in training personnel to provide comprehensive education about synthetic progestins, thereby bolstering this distribution channel's growth.

Retail Pharmacies:

Retail pharmacies serve as a vital distribution channel for synthetic progestins, providing accessibility and convenience for consumers. Many women prefer purchasing contraceptives and hormonal treatments directly from pharmacies due to their proximity and ease of access. The growing acceptance of over-the-counter contraceptive options further strengthens this segment, as women increasingly seek to manage their reproductive health on their terms. Additionally, retail pharmacies are often the first point of contact for women seeking information regarding options available, thereby enhancing their role in educating consumers about synthetic progestins. The expansion of pharmacy chains and community pharmacies is expected to drive this segment forward.

Online Pharmacies:

The rise of online pharmacies represents a significant shift in the distribution landscape for synthetic progestins. The convenience and discretion associated with purchasing medications online have attracted a growing number of consumers, particularly younger demographics who are more inclined to shop digitally. This distribution channel allows women to obtain contraceptives and hormone therapies without the potential stigma associated with in-person visits to pharmacies. Moreover, the COVID-19 pandemic accelerated the adoption of online shopping for pharmaceuticals, leading to sustained interest in this channel. As regulations evolve to accommodate online sales of medications, this segment is poised for growth within the synthetic progestin market.

Drug Stores:

Drug stores play an essential role in the distribution of synthetic progestins, serving as a reliable source for consumers seeking hormonal medications. These stores often carry a variety of progestin products, including oral contraceptives and topical treatments, making them accessible to a broad consumer base. Additionally, drug stores frequently offer consultations or advice from pharmacists, further enhancing the customer experience. The continued expansion of drug store chains and their efforts to meet the needs of local communities contribute to this distribution channel's growth. As awareness of women's health issues increases, drug stores are likely to become increasingly prominent in the synthetic progestin market.

By Ingredient Type

Drospirenone:

Drospirenone is a synthetic progestin that has gained popularity due to its unique properties, including its anti-androgenic effects, which can help reduce acne and other symptoms associated with hormonal fluctuations. This ingredient is mainly used in combination contraceptives and is known for its potential to improve menstrual regulation and reduce premenstrual syndrome symptoms. The increasing demand for products containing drospirenone reflects a growing awareness of the need for tailored hormonal therapies that address not just contraception but also related health issues. As research continues to uncover its benefits, drospirenone-containing products are likely to see sustained growth.

Levonorgestrel:

Levonorgestrel is one of the most widely used synthetic progestins in contraceptive products, known for its effectiveness in preventing pregnancy. It is included in both oral contraceptives and emergency contraceptive pills, making it a versatile ingredient. The rising demand for effective contraceptive options drives the market for levonorgestrel, particularly in regions with high unmet contraceptive needs. Furthermore, ongoing research exploring its potential applications in managing hormonal disorders continues to promote levonorgestrel's presence in the market. As access to contraceptive options expands globally, the demand for levonorgestrel products is expected to remain strong.

Medroxyprogesterone:

Medroxyprogesterone is another prominent synthetic progestin, commonly utilized in injectable contraceptives and hormone replacement therapy. Its long-acting nature makes it a preferred choice among women seeking a reliable birth control method with minimal interference in their daily lives. Additionally, medroxyprogesterone has applications in treating various menstrual disorders and endometriosis, further strengthening its market position. The growing recognition of the importance of effective hormonal management is expected to enhance demand for products containing medroxyprogesterone. As healthcare professionals continue to advocate for its benefits, this ingredient is expected to remain a significant player in the synthetic progestin market.

Norethindrone:

Norethindrone is a synthetic progestin that has been widely used in both oral contraceptives and hormone replacement therapies. Its effectiveness in regulating menstrual cycles and alleviating the symptoms associated with premenstrual syndrome positions it prominently within the synthetic progestin market. The increasing awareness of women's health issues and the demand for effective hormonal treatments are key drivers of norethindrone's market growth. As more women seek options to manage hormonal imbalances and related conditions, the use of norethindrone-containing products is likely to expand, contributing positively to the market landscape.

Etonogestrel:

Etonogestrel is a newer synthetic progestin that is primarily used in contraceptive implants and vaginal rings. Its long-term effectiveness and low maintenance requirements make it increasingly appealing to women looking for reliable contraceptive options. Etonogestrel's ability to provide pregnancy prevention for extended periods without the need for daily intervention has contributed to its rising popularity. Additionally, as healthcare providers continue to promote the benefits of long-acting reversible contraceptives (LARCs), etonogestrel is likely to see increased adoption in family planning discussions. The continued focus on expanding access to innovative contraceptive methods will further bolster the demand for etonogestrel-containing products.

By Region

The North America synthetic progestin market is anticipated to witness substantial growth, propelled by the increasing prevalence of hormonal disorders and the rising demand for effective contraceptive options. The region's advanced healthcare infrastructure and high awareness levels about reproductive health contribute significantly to market expansion. In addition, the growing trend of healthcare digitization has enhanced accessibility to hormone therapies through online pharmacies and telemedicine. The North American market is projected to grow at a CAGR of 6.5% during the forecast period, reflecting the region's leadership in the adoption of innovative healthcare solutions. As more women seek hormonal therapies, the market is expected to continue flourishing.

Europe is another crucial region in the synthetic progestin market, characterized by a strong emphasis on women's health and reproductive rights. The increasing support for family planning initiatives and the availability of a wide range of contraceptive options contribute to the growth of this market segment. Moreover, the rising number of healthcare campaigns aimed at raising awareness of hormonal disorders and their management further augments market growth. The European synthetic progestin market is expected to grow at a CAGR of 5.8%, driven by an increase in the adoption of effective contraceptive solutions and hormone therapies. The region's commitment to advancing healthcare access for women will play a significant role in shaping market trends and opportunities.

Opportunities

One of the most significant opportunities in the synthetic progestin market lies in the development of new formulations and delivery methods that cater to a broader range of consumers. As research and development efforts focus on creating more effective and safer synthetic progestins, there is potential for innovation in product design, such as long-acting injectables, implants, and transdermal systems. These advancements can enhance patient compliance and satisfaction, ultimately leading to increased market penetration. Furthermore, addressing the diverse needs of different demographics, including adolescents and older women, presents a unique opportunity for growth, as tailored solutions can significantly impact the quality of life for these populations.

Another opportunity within the synthetic progestin market stems from the growing demand for personalized medicine and more targeted hormone therapies. As healthcare moves towards individualized treatment plans, understanding the unique hormonal profiles of patients can lead to more precise therapies. This shift provides an avenue for companies to develop customized synthetic progestin options that address specific conditions or patient preferences, thereby enhancing the overall effectiveness of treatment regimens. As healthcare providers increasingly prioritize personalized approaches, companies that invest in research and product development focused on individualized therapies will likely find themselves at the forefront of market growth.

Threats

The synthetic progestin market faces several threats, including potential regulatory challenges that may hinder product approval and bring about increased scrutiny on pharmaceutical companies. With ever-evolving regulations and safety standards, manufacturers may encounter difficulties in bringing new products to market or may face significant delays in the approval process. This situation can inhibit innovation and slow down the availability of new therapies, ultimately impacting market dynamics. Furthermore, any adverse events or negative publicity surrounding synthetic progestins could lead to decreased consumer confidence and demand, posing a challenge to manufacturers seeking to sustain growth.

Additionally, the threat of competition from alternative contraceptive methods, including natural alternatives and non-hormonal options, poses a significant challenge to the synthetic progestin market. The rising popularity of fertility awareness methods, barrier methods, and non-hormonal IUDs could divert consumer attention away from synthetic progestins, particularly among health-conscious individuals seeking to avoid hormonal interventions. As the market diversifies, manufacturers will need to adapt their offerings to address changing consumer preferences and expectations in order to maintain their market share.

Competitor Outlook

• Bayer AG
• Pfizer Inc.
• Teva Pharmaceuticals
• Merck & Co., Inc.
• HRA Pharma
• Amgen Inc.
• AbbVie Inc.
• Sun Pharmaceutical Industries Ltd.
• Janssen Pharmaceuticals (Johnson & Johnson)
• Gedeon Richter Plc
• Mylan N.V.
• Sandoz International GmbH
• Novartis AG
• Ferring Pharmaceuticals
• Hoffmann-La Roche Ltd.

The competitive landscape of the synthetic progestin market is characterized by a mix of well-established pharmaceutical companies and emerging players. Major market participants are actively engaged in extensive research and development activities to enhance their product offerings, improve efficacy, and reduce side effects associated with synthetic progestins. The focus on innovation and technological advancements is crucial for maintaining a competitive edge as the market evolves. Collaborations, partnerships, and mergers and acquisitions are also common strategies employed by companies to expand their market reach and diversify their portfolios in response to changing consumer preferences and regulatory landscapes.

Bayer AG is one of the leading players in the synthetic progestin market, known for its extensive range of contraceptive products that include popular brands like Yaz and Mirena. The company's commitment to research and development has led to continuous innovations in contraceptive formulations, positioning them as a trusted name in reproductive health. Pfizer Inc. is another key competitor, with a strong presence in the hormonal therapy market. The company focuses on providing comprehensive solutions for managing hormonal disorders and offers a range of synthetic progestin products that cater to diverse consumer needs.

Merck & Co., Inc. also plays a significant role in the market, offering a variety of synthetic progestins through its contraceptive and hormone replacement products. Their commitment to improving women's health through research-driven solutions has established them as a reputable brand. Additionally, companies like Teva Pharmaceuticals and HRA Pharma are gaining traction by innovating their product lines to attract a broader consumer base, particularly focusing on personalized and effective healthcare solutions. As the market continues to grow, competition is expected to intensify, driving advancements and improvements in synthetic progestin offerings.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Bayer AG
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 HRA Pharma
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Mylan N.V.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 AbbVie Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Novartis AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Pfizer Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Gedeon Richter Plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Teva Pharmaceuticals
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hoffmann-La Roche Ltd.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Ferring Pharmaceuticals
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Sandoz International GmbH
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Janssen Pharmaceuticals (Johnson & Johnson)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Synthetic Progestin Market, By Application
    • 6.1.1 Contraception
    • 6.1.2 Menstrual Disorders
    • 6.1.3 Hormone Replacement Therapy
    • 6.1.4 Endometriosis
    • 6.1.5 Others
  • 6.2 Synthetic Progestin Market, By Product Type
    • 6.2.1 Oral Contraceptives
    • 6.2.2 Injectable Progestins
    • 6.2.3 Progestin-releasing Intrauterine Devices
    • 6.2.4 Progestin Implants
    • 6.2.5 Progestin Creams
  • 6.3 Synthetic Progestin Market, By Ingredient Type
    • 6.3.1 Drospirenone
    • 6.3.2 Levonorgestrel
    • 6.3.3 Medroxyprogesterone
    • 6.3.4 Norethindrone
    • 6.3.5 Etonogestrel
  • 6.4 Synthetic Progestin Market, By Distribution Channel
    • 6.4.1 Hospitals & Clinics
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Synthetic Progestin Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Synthetic Progestin market is categorized based on

By Product Type

• Oral Contraceptives
• Injectable Progestins
• Progestin-releasing Intrauterine Devices
• Progestin Implants
• Progestin Creams

By Application

• Contraception
• Menstrual Disorders
• Hormone Replacement Therapy
• Endometriosis
• Others

By Distribution Channel

• Hospitals & Clinics
• Retail Pharmacies
• Online Pharmacies
• Drug Stores

By Ingredient Type

• Drospirenone
• Levonorgestrel
• Medroxyprogesterone
• Norethindrone
• Etonogestrel

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Bayer AG
• Pfizer Inc.
• Teva Pharmaceuticals
• Merck & Co., Inc.
• HRA Pharma
• Amgen Inc.
• AbbVie Inc.
• Sun Pharmaceutical Industries Ltd.
• Janssen Pharmaceuticals (Johnson & Johnson)
• Gedeon Richter Plc
• Mylan N.V.
• Sandoz International GmbH
• Novartis AG
• Ferring Pharmaceuticals
• Hoffmann-La Roche Ltd.